Inventory of Supplemental Information
Figure S1
• Flow cytometry data with cell surface marker expression of isolated mesenchymal stem cells and c-kit+ cells. Representative quality control data.
• Supplemental to Figure 1 and 2.
Figure S2
• Analysis of endogenous progenitor activity in the right ventricle after myocardial infarction. There is evidence of progenitor activity in the right ventricle after myocardial infarction 8 wks after MI, but no evidence of increased activity in the hearts of mice administered c-kit+ cells. 
Figure S3
• Analysis of BrdU+ cardiomyocytes after MI and cell therapy, as a function of GFP/β-galactosidase expression. C-kit+ cell therapy leads to an increase in BrdU+ cardiomyocytes compared to vehicle, yet the majority of BrdU+ cardiomyocytes are GFP-consistent with progenitor proliferation and differentiation.
• Analysis of cardiomyocyte cross-sectional area as a function of GFP/β-galactosidase expression, demonstrated equivalent size in the uninjured heart but hypertrophy in preexisting GFP+ cardiomyocytes with injury. This supports the concept that there are no baseline differences between the GFP+ and β-galactosidase+ cardiomyocyte populations.
• Supplemental to Figure 1 .
Figure S4
• Infarct size data suggesting no inter-group differences in the size of the experimental myocardial infarctions.
• Complete hemodynamic data for c-kit+ cell and mesenchymal stem cell treated mice, compared to control.
Figure S5
• Echocardiographic data demonstrating no discernable evidence of cardiotoxicity with the 4-OH-tamoxifen protocol. Important control for cardiac function data derived from mice treated with 4-OH-tamoxifen. Figure S3 . After MI the β-galactosidase+ pool demonstrates characteristics consistent with a higher frequency of both smaller and BrdU+ cardiomyocytes (see Figure 1) . A. BrdU+/troponin+ cardiomyocytes after either administration of c-kit+ cells or vehicle control. In both groups, the majority of BrdU+ cardiomyocytes are GFP-consistent with proliferation and differentiations of GFP-precursors. Data expressed as mean ± SEM. B. Cross-sectional area of β-galactosidase+ versus GFP+ cardiomyocytes. In the absence of injury (sham surgery) there is no difference in the size of the two populations. After MI, in all groups, there the GFP+ cardiomyocytes are significantly larger than β-galactosidase+ cardiomyocytes. Data expressed as mean ± SEM. Figure S4 . Infarct size and hemodynamic data 8 weeks after sham surgery or myocardial infarction and treatment with vehicle control, c-kit+ cells, or mesenchymal stem cells (see Figure 2) . A. Infarct size determined by measurement of scar in serial trichrome stained sections at multiple ventricular levels. Infarct size between all MI groups was similar. Data expressed as mean ± SEM. B. Table with hemodynamic data derived from blinded terminal cardiac catheterization performed 8 weeks after MI. *p<0.05. Data expressed as mean ± SEM. Figure S5 . Reversible cardiotoxicity resulting from high-dose tamoxifen and 4-OH-tamoxifen, but not from a 14-day low dose protocol. High-dose experiment represented in the left-hand column. Mice were treated with oil (control), tamoxifen, or 4-OH-tamoxifen (80mg/kg/day) for 5 days (see Figure 2 ). Echocardiograms were performed at day 0, day 5, and day 19. *p<0.05. Low-dose experiment represented in the right-hand column. Echocardiograms were performed at the completion of the 14-day dosing protocol (20mg/kg/day). No significant differences were noted in echocardiographic parameters of ventricular remodeling or function. EDD=end diastolic dimension; ESD=end systolic dimension; FS=fractional shortening. Data expressed as mean ± SEM.
